Avatrombopag Maleate 20mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20mg

Reference Brands: Doptelet (USA)

Category: Blood Disorder

Avatrombopag is an oral thrombopoietin (TPO) receptor agonist that stimulates megakaryocyte proliferation and differentiation, thereby increasing platelet production. It is indicated for adult patients with thrombocytopenia due to chronic liver disease who are scheduled for an invasive procedure, and also for chronic immune thrombocytopenia (ITP) when other treatments are insufficient. It helps avoid platelet transfusions and reduce bleeding risk by raising platelet counts prior to procedures.

Product Description:

Avatrombopag is an oral agonist at the thrombopoietin receptor, the receptor that drives platelet production. It binds at a site distinct from where natural thrombopoietin binds, so it stimulates megakaryocyte proliferation without competing with the body's own hormone. Its practical advantage over the earlier drug in this class is that it does not require food restrictions around dosing and does not carry the same hepatotoxicity signal — it is taken with food rather than in a rigid window away from calcium.

It is used to raise platelet counts before invasive procedures in adults with chronic liver disease, and for chronic immune thrombocytopenia inadequately controlled by other treatments. The first use is the more interesting one commercially: a patient with cirrhosis needing a biopsy, dental extraction or surgery has traditionally received platelet transfusions, with their cost, delay and transfusion risk. A five-day oral course beforehand replaces that. Headache, fatigue and thrombosis are the main adverse effects.

Sourcing notes. Originator product, on patent. The pre-procedure indication means short defined courses rather than continuous therapy, so demand is episodic and tied to hepatology and endoscopy volumes. Confirm registration per destination. Oral tablets taken with food; room temperature.